Evaluation of a New Imagingtechnologie for Thrombosis
Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Arterial and venous thrombi play an important role in various vascular diseases such as
myocardial infarction, stroke, transient ischemic attacks (TIA) and pulmonary embolism. These
thromboembolic disorders are the leading causes of morbidity and mortality worldwide. A
non-invasive method for the quantitative and effective detection of thrombi in the whole body
has not yet been established. In spite of the available techniques, 30% to 40% of ischemic
strokes "cryptogenic" (undetermined cause, the source of thromboembolism is never
identified). Possible causes of cryptogenic stroke atherosclerosis include in the aortic arch
or intracranial arteries. A plaque in the arch or other large vessels could be an important
source of cryptogenic strokes, however, are those difficult to detect by routine methods. The
approach of thrombus targeted molecular imaging could identify potentially troublesome
plaques early on before they become a dangerous rupture. The hypothesis is that the
radiotracer 18F-arterial GP1 and venous thrombi using positron emission tomography (PET) can
be made visible. The primary goal is the potential applicability of the substance as a PET
tracer for diagnosing thrombi.